Courthouse News Top Download

NEWARK, N.J. – Allergan faces a federal class action from shareholders over the drugmaker’s 41 percent stock drop, from $319.47 in 2015 to $188.82 last month, upon news that it could face criminal charges for colluding to fix the prices of generic pharmaceuticals.